News from daiichi sankyo, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 29, 2015, 17:00 ET

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine (NEJM)...

Jul 13, 2015, 04:09 ET

NICE recommends once-daily LIXIANA® ▼ (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

NICE Final Appraisal Determination recommends that edoxaban is a cost effective use of NHS resources   The National Institute for Health...

Jul 09, 2015, 19:01 ET

New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice"

  Launch comes as new patients' survey reveals a significant proportion still not receiving adequate treatment for atrial fibrillation, the...

Jun 18, 2015, 08:00 ET

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational study, which...

Apr 01, 2015, 08:00 ET

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

 Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company,...

Mar 19, 2015, 06:00 ET

Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US

 Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US, in line with...

Feb 09, 2015, 07:59 ET

SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that SAVAYSA™ (edoxaban), an oral, once-daily selective factor...

Feb 04, 2015, 08:00 ET

Daiichi Sankyo Announces First Patients in Large-Scale, Multi-National Phase 3 Clinical Programs for Mirogabalin

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced enrollment of the first patients in large-scale, multi-national...

Jan 09, 2015, 10:09 ET

Daiichi Sankyo, Inc. Announces Civil Settlement

Daiichi Sankyo, Inc. ("the Company") announced today that it has reached a civil settlement with the U.S. Government, as...

Jan 08, 2015, 22:03 ET

U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Dec 08, 2014, 07:09 ET

Daiichi Sankyo Launches New Formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA® 60 mg...

Dec 04, 2014, 16:40 ET

Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and...

Nov 10, 2014, 19:37 ET

Daiichi Sankyo and Ambit Announce Results of Tender Offer

Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences)...

Oct 30, 2014, 20:08 ET
Oct 14, 2014, 16:43 ET

Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation

 On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned...

Sep 29, 2014, 18:28 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo va acquérir Ambit Biosciences

-- Le composé chimique phare, le Quizartinib, va renforcer le portefeuille de traitements cancérologiques de Daiichi Sankyo Daiichi...

Sep 29, 2014, 13:03 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo adquiere Ambit Biosciences

-- El principal compuesto, quizartinib, construirá la gama de oncología de Daiichi Sankyo Daiichi Sankyo Company, Ltd. (de...

Sep 29, 2014, 12:50 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo wird Ambit Biosciences übernehmen

-- Leitwirkstoff Quizartinib kommt dem weiteren Ausbau der Onkologie-Pipeline von Daiichi Sankyo zugute Daiichi Sankyo Company, Ltd....

Sep 28, 2014, 19:07 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences (NASDAQ: AMBI), jointly announced today that they have...

Sep 26, 2014, 07:00 ET

Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it received approval from the Ministry of Health, Labour and...